Open AccessExtending the Platinum‐Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second‐Line Chemotherapy
Author(s) -
Bookman Michael A.
Publication year - 1999
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.4-2-87
Subject(s) - topotecan , medicine , ovarian cancer , paclitaxel , oncology , chemotherapy , platinum , drug , pharmacology , cancer , biochemistry , chemistry , catalysis
Although the combination of platinum and paclitaxel offers effective chemotherapy for advanced ovarian cancer, the majority of women will eventually relapse with development of drug‐resistant disease. Topotecan is the most extensively studied agent currently available for management of recurrent ovarian cancer and has been approved by the FDA for that particular indication. Early use of topotecan offers an effective and tolerable strategy that can prolong the platinum‐free interval and optimize subsequent retreatment with platinum.